The University of Tokyo · Medicine
Professor Yuta Suzuki's research lab specializes in cardiovascular and metabolic health, with a focus on real-world outcomes of diabetes and hypertension management. The lab investigates the comparative effectiveness of diabetes medications—particularly SGLT2 inhibitors—on cardiovascular and cerebrovascular outcomes, as well as the dose-dependent impact of blood pressure and glucose levels on aortic diseases. Using large-scale population-based databases, the lab explores risk stratification, early detection, and prevention strategies for hypertension and related complications in young and middle-aged adults. The research also extends to biomechanics, examining movement patterns in athletes to inform injury prevention and performance optimization.
Figures are computed from collected data and may differ slightly.
The risks for subsequent development of HF, MI, AP, stroke, and AF were comparable between individual SGLT2 inhibitors. This is the first study comparing the wide-range cardiovascular outcomes of patients with DM treated with individual SGLT2 inhibitors using large-scale real-world data.
The purpose of this study was to investigate differences in the support leg joint moment and moment power between side-step (SS) and cross-step (CS) cutting techniques with a prescribed 90 degrees cutting angle. Ground reaction forces (1,000Hz) and three-dimensional kinematics (250Hz) of SS and CS cutting techniques were collected from 20 male college athletes. Normalised peak knee extension moment was larger in the SS technique than in the CS technique (0.40 +/- 0.10 in SS; 0.26 +/- 0.08 in CS)
Abstract Aims Data on the dose-dependent association of blood pressure (BP) and fasting plasma glucose (FPG) level with the risk of aortic dissection (AD) and aortic aneurysm (AA) are limited. Methods and results This observational cohort study included 3 358 293 individuals registered in a health checkup and claims database in Japan [median age, 43 (36–51) years; 57.2% men]. Individuals using BP- or glucose-lowering medications or those with a history of cardiovascular disease were excluded. In
CVH metrics can stratify the risk for hypertension in non-hypertensive adults aged 20-39 years. These findings have important public health implications for the screening and prevention of hypertension. Improving CVH metrics may prevent the risk of developing hypertension in young adults.
Background The prevalence of hypertension subtypes changes with age. However, little is known regarding the age-dependent association of hypertension subtypes with incident heart failure (HF). Methods and Results We conducted an observational cohort study including 2 612 570 people (mean age, 44.0 years; 55.0% men). No participants were taking blood pressure-lowering medications or had a known history of cardiovascular disease. Participants were categorized as aged 20 to 49 years (n=1 825 756),
Our analysis using large-scale real-world data demonstrated the potential advantage of SGLT2 inhibitors over DPP4 inhibitors in patients with MAFLD and DM.
Open papers in the app to read, cite, and organize with AI.
